Global Small Molecule Drug Discovery Market By Phase (Target Validation and Identification, Hit and Lead Generation, Lead optimization and Profiling, Clinical Trials), By Therapeutic Indication (Mental Disorder, Oncology, Cardiovascular, Central Nervous System (CNS) Disorders, Respiratory, Gastrointestinal, Others), By End User (Pharmaceutical Companies, Research Labs and Centers, Others), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2022 – 2030
Industry Trends
Small molecules have a molecular weight of less than 900 Da. 90 percent of pharmaceutical medications are made up of small molecules (such as insulin, aspirin, and antihistamines). Small molecules can be employed as anticancer medications in innovative cancer therapies by inhibiting specific proteins in cancer cells. These small-molecule inhibitors disrupt certain protein pathways, which can reduce cancer cell formation and proliferation. The process of discovering small molecule drugs can be complex and difficult. A typical procedure begins with hit identification and assay development and continues to the selection of preclinical candidates. The high-throughput screening of drug candidates is important in the drug discovery process. The increasing applications of small molecule medications in the treatment of chronic illnesses is driving up the demand for small molecule drug discovery market. Furthermore, an increase in cancer cases is likely to boost market growth during the forecast period.
According to the American Cancer Society, around 1.8 million new cancer cases were expected to be identified in 2020, with roughly 606,520 cancer deaths occurring in the United States. Furthermore, by collaborating with other players, the small molecule drug discovery market's leading players contribute to its growth. For instance, LifeMine Therapeutics Inc., a biopharmaceutical company reinventing medication discovery by mining genetically-encoded small molecules (GEMs) from the biosphere, announced a strategic research and development collaboration with GlaxoSmithKline in March 2022. GSK will have access to LifeMine's genomically enabled drug discovery platform in order to identify innovative small molecule leads directed to up to three human targets specified by GSK and address different disease areas.
The World Health Organization declared COVID-19 a pandemic on March 11th, and it has caused millions of cases and a quarter million deaths since then. Clinical manifestations of this disease include pneumonia, lung injury, inflammation, and severe acute respiratory syndrome (SARS). Through an in-depth study of the infection mechanism during pandemic, scientists expect to design and discover novel small-molecule candidate drugs targeting key proteins in the SARS-CoV-2 life cycle. Researchers from Germany's Goethe University discovered 69 small molecules that can bind to SARS-CoV-2 segments, potentially halting or slowing viral replication. Furthermore, the increased promise of innovation in drug discovery will provide new opportunities for market participants in the small molecule drug discovery market to grow in the near future.
In terms of revenue, the global small molecule drug discovery market was valued at US$ 37,634.21 Mn in 2021 growing at a CAGR of 10.02% over the forecast period (2022 – 2030). The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Small Molecule Drug Discovery Market Revenue & Forecast, (US$ Million), 2015 – 2030
Phase Outlook:
Based on the phase, the global small molecule drug discovery market has been divided into target validation and identification, hit and lead generation, lead optimization and profiling, and clinical trials. Among these segments, hit and lead generation held the highest share of the small molecule drug discovery market in 2021, owing to growing investment in drug discovery and the rising demand for cost-effective therapeutics. One of the most important steps in the drug discovery process is lead generation. High-throughput screening (HTS) of corporate compound decks has emerged as the primary paradigm for hit or lead discovery over the last decade.
Therapeutic Indication Outlook:
Based on therapeutic indication, the global small molecule drug discovery market has been classified into a mental disorders, oncology, cardiovascular, central nervous system (CNS) disorders, respiratory, gastrointestinal, and others. The oncology indication accounted for a substantial share of the market in 2021, owing to an increase in small molecule drug approvals and a growing pipeline of cancer therapeutics. Furthermore, market participants are actively involved in market growth through collaboration with other players. For example, Eli Lilly and Company and Kumquat Biosciences announced an exclusive collaboration in July 2021 to focus on the discovery, development, and commercialization of potential innovative small molecules that stimulate tumor-specific immune responses. Kumquat will use its small molecule immuno-oncology (IO) platform to discover novel clinical candidates over the duration of the multi-year collaboration, and Lilly will have the option to select a particular number of drug candidates for some further development and commercialization globally.
End Users Outlook:
Based on end-users, the global small molecule drug discovery market has been classified into pharmaceutical companies, research labs and centers, and others. The pharmaceutical companies segment is likely to be one of the most prominent segments over the forecast period due to increased spending on targeted therapies and the availability of innovative technology in laboratories. For nearly a century, small molecule drugs have been the pharmaceutical industry's mainstay. The rapid advancement of biopharmaceutical research and technology creates opportunities for novel and creative approaches to the development of small-molecule drugs. In recent years, advances in prediction, structure-based design, and imaging, as well as automation, artificial intelligence, and machine learning, have become critical enablers for increasing the speed and success rates of small molecule lead optimization.
Region Outlook:
Based on regions, Asia Pacific is predicted to grow at the fastest rate during the forecast period 2022 – 2030 owing to growing healthcare spending for infrastructure improvements and increasing research and development (R&D) activities in the region. Growing cancer cases in the region's major economies, such as China and India, is expected to drive small molecule drug discovery market growth in the coming years. According to the National Cancer Registry Programs, India's cancer patient population for 2020 was 1,392,179, with the top five cancer sites being lung, breast, mouth, cervix uteri, and tongue.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of small molecule drug discovery market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the global small molecule drug discovery market are listed below:
- AbbVie Inc.
- Boehringer Ingelheim International GmbH
- Bristol-Myers Squibb Company
- Charles River Laboratories
- Eli Lilly and Company
- Gilead Sciences, Inc.
- GlaxoSmithKline plc
- Johnson and Johnson Services, Inc.
- Labcorp Drug Development
- Merck KGaA
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Other Market Participants
Global Small Molecule Drug Discovery Market:
- By Phase
- Target Validation and Identification
- Hit and lead generation
- Lead optimization and Profiling
- Clinical Trials
- By Therapeutic Indication
- Mental Disorder
- Oncology
- Cardiovascular
- Central nervous system (CNS) disorders
- Respiratory
- Gastrointestinal
- Others
- By End Users
- Pharmaceutical Companies
- Research Labs and Centers
- Others
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1.
Market
Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Historic Years: 2015 - 2021
1.2.2. Base Year: 2021
1.2.3. Forecast Years: 2022 – 2030
2.
Key
Target Audiences
3.
Research
Methodology
3.1. Primary Research
3.1.1. Research Questionnaire
3.1.2. Global Percentage Breakdown
3.1.3. Primary Interviews: Key Opinion Leaders
(KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation Methodology
3.5. Research Assumptions
4.
Recommendations
and Insights from AMI’s Perspective**
5.
Holistic
Overview of Small Molecule Drug Discovery Market
6.
Market
Synopsis: Small Molecule Drug Discovery
Market
7.
Small
Molecule Drug Discovery Market Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.2.4. Challenges
7.3. Trends in Small Molecule Drug Discovery
Market
7.4. Market Determinants Radar Chart
7.5. Macro-Economic and Micro-Economic Indicators:
Small Molecule Drug Discovery Market
7.6. Porter’s Five Force Analysis
7.7. Impact of Covid-19 on Small Molecule Drug
Discovery Market
8.
Global
Small Molecule Drug Discovery Market Analysis and Forecasts, 2022 – 2030
8.1. Overview
8.1.1. Global Small Molecule Drug Discovery Market
Revenue (US$ Mn)
8.2. Global Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
8.2.1. Target Validation and Identification
8.2.1.1.
Definition
8.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.1.3.
Market
Forecast, 2022 - 2030
8.2.1.4.
Compound
Annual Growth Rate (CAGR)
8.2.1.5.
Regional
Bifurcation
8.2.1.5.1.
North
America
8.2.1.5.1.1. Market Estimation, 2015 - 2021
8.2.1.5.1.2. Market Forecast, 2022 - 2030
8.2.1.5.2.
Europe
8.2.1.5.2.1. Market Estimation, 2015 - 2021
8.2.1.5.2.2. Market Forecast, 2022 - 2030
8.2.1.5.3.
Asia
Pacific
8.2.1.5.3.1. Market Estimation, 2015 - 2021
8.2.1.5.3.2. Market Forecast, 2022 - 2030
8.2.1.5.4.
Middle
East and Africa
8.2.1.5.4.1. Market Estimation, 2015 - 2021
8.2.1.5.4.2. Market Forecast, 2022 - 2030
8.2.1.5.5.
Latin
America
8.2.1.5.5.1. Market Estimation, 2015 - 2021
8.2.1.5.5.2. Market Forecast, 2022 - 2030
8.2.2. Hit and lead generation
8.2.2.1.
Definition
8.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.2.3.
Market
Forecast, 2022 - 2030
8.2.2.4.
Compound
Annual Growth Rate (CAGR)
8.2.2.5.
Regional
Bifurcation
8.2.2.5.1.
North
America
8.2.2.5.1.1. Market Estimation, 2015 - 2021
8.2.2.5.1.2. Market Forecast, 2022 - 2030
8.2.2.5.2.
Europe
8.2.2.5.2.1. Market Estimation, 2015 - 2021
8.2.2.5.2.2. Market Forecast, 2022 - 2030
8.2.2.5.3.
Asia
Pacific
8.2.2.5.3.1. Market Estimation, 2015 - 2021
8.2.2.5.3.2. Market Forecast, 2022 - 2030
8.2.2.5.4.
Middle
East and Africa
8.2.2.5.4.1. Market Estimation, 2015 - 2021
8.2.2.5.4.2. Market Forecast, 2022 - 2030
8.2.2.5.5.
Latin
America
8.2.2.5.5.1. Market Estimation, 2015 - 2021
8.2.2.5.5.2. Market Forecast, 2022 - 2030
8.2.3. Lead optimization and Profiling
8.2.3.1.
Definition
8.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.3.3.
Market
Forecast, 2022 - 2030
8.2.3.4.
Compound
Annual Growth Rate (CAGR)
8.2.3.5.
Regional
Bifurcation
8.2.3.5.1.
North
America
8.2.3.5.1.1. Market Estimation, 2015 - 2021
8.2.3.5.1.2. Market Forecast, 2022 - 2030
8.2.3.5.2.
Europe
8.2.3.5.2.1. Market Estimation, 2015 - 2021
8.2.3.5.2.2. Market Forecast, 2022 - 2030
8.2.3.5.3.
Asia Pacific
8.2.3.5.3.1. Market Estimation, 2015 - 2021
8.2.3.5.3.2. Market Forecast, 2022 - 2030
8.2.3.5.4.
Middle
East and Africa
8.2.3.5.4.1. Market Estimation, 2015 - 2021
8.2.3.5.4.2. Market Forecast, 2022 - 2030
8.2.3.5.5.
Latin
America
8.2.3.5.5.1. Market Estimation, 2015 - 2021
8.2.3.5.5.2. Market Forecast, 2022 - 2030
8.2.4. Clinical Trials
8.2.4.1.
Definition
8.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
8.2.4.3.
Market
Forecast, 2022 - 2030
8.2.4.4.
Compound
Annual Growth Rate (CAGR)
8.2.4.5.
Regional
Bifurcation
8.2.4.5.1.
North
America
8.2.4.5.1.1. Market Estimation, 2015 - 2021
8.2.4.5.1.2. Market Forecast, 2022 - 2030
8.2.4.5.2.
Europe
8.2.4.5.2.1. Market Estimation, 2015 - 2021
8.2.4.5.2.2. Market Forecast, 2022 - 2030
8.2.4.5.3.
Asia
Pacific
8.2.4.5.3.1. Market Estimation, 2015 - 2021
8.2.4.5.3.2. Market Forecast, 2022 - 2030
8.2.4.5.4.
Middle
East and Africa
8.2.4.5.4.1. Market Estimation, 2015 - 2021
8.2.4.5.4.2. Market Forecast, 2022 - 2030
8.2.4.5.5.
Latin
America
8.2.4.5.5.1. Market Estimation, 2015 - 2021
8.2.4.5.5.2. Market Forecast, 2022 - 2030
8.3. Key Segment for Channeling Investments
8.3.1. By Phase
9.
Global
Small Molecule Drug Discovery Market Analysis and Forecasts, 2022 – 2030
9.1. Overview
9.2. Global Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
9.2.1. Mental Disorder
9.2.1.1.
Definition
9.2.1.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.1.3.
Market
Forecast, 2022 - 2030
9.2.1.4.
Compound
Annual Growth Rate (CAGR)
9.2.1.5.
Regional
Bifurcation
9.2.1.5.1.
North
America
9.2.1.5.1.1. Market Estimation, 2015 - 2021
9.2.1.5.1.2. Market Forecast, 2022 - 2030
9.2.1.5.2.
Europe
9.2.1.5.2.1. Market Estimation, 2015 - 2021
9.2.1.5.2.2. Market Forecast, 2022 - 2030
9.2.1.5.3.
Asia
Pacific
9.2.1.5.3.1. Market Estimation, 2015 - 2021
9.2.1.5.3.2. Market Forecast, 2022 - 2030
9.2.1.5.4.
Middle
East and Africa
9.2.1.5.4.1. Market Estimation, 2015 - 2021
9.2.1.5.4.2. Market Forecast, 2022 - 2030
9.2.1.5.5.
Latin
America
9.2.1.5.5.1. Market Estimation, 2015 - 2021
9.2.1.5.5.2. Market Forecast, 2022 - 2030
9.2.2. Oncology
9.2.2.1.
Definition
9.2.2.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.2.3.
Market
Forecast, 2022 - 2030
9.2.2.4.
Compound
Annual Growth Rate (CAGR)
9.2.2.5.
Regional
Bifurcation
9.2.2.5.1.
North
America
9.2.2.5.1.1. Market Estimation, 2015 - 2021
9.2.2.5.1.2. Market Forecast, 2022 - 2030
9.2.2.5.2.
Europe
9.2.2.5.2.1. Market Estimation, 2015 - 2021
9.2.2.5.2.2. Market Forecast, 2022 - 2030
9.2.2.5.3.
Asia
Pacific
9.2.2.5.3.1. Market Estimation, 2015 - 2021
9.2.2.5.3.2. Market Forecast, 2022 - 2030
9.2.2.5.4.
Middle
East and Africa
9.2.2.5.4.1. Market Estimation, 2015 - 2021
9.2.2.5.4.2. Market Forecast, 2022 - 2030
9.2.2.5.5.
Latin
America
9.2.2.5.5.1. Market Estimation, 2015 - 2021
9.2.2.5.5.2. Market Forecast, 2022 - 2030
9.2.3. Cardiovascular
9.2.3.1.
Definition
9.2.3.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.3.3.
Market
Forecast, 2022 - 2030
9.2.3.4.
Compound
Annual Growth Rate (CAGR)
9.2.3.5.
Regional
Bifurcation
9.2.3.5.1.
North America
9.2.3.5.1.1. Market Estimation, 2015 - 2021
9.2.3.5.1.2. Market Forecast, 2022 - 2030
9.2.3.5.2.
Europe
9.2.3.5.2.1. Market Estimation, 2015 - 2021
9.2.3.5.2.2. Market Forecast, 2022 - 2030
9.2.3.5.3.
Asia
Pacific
9.2.3.5.3.1. Market Estimation, 2015 - 2021
9.2.3.5.3.2. Market Forecast, 2022 - 2030
9.2.3.5.4.
Middle
East and Africa
9.2.3.5.4.1. Market Estimation, 2015 - 2021
9.2.3.5.4.2. Market Forecast, 2022 - 2030
9.2.3.5.5.
Latin
America
9.2.3.5.5.1. Market Estimation, 2015 - 2021
9.2.3.5.5.2. Market Forecast, 2022 - 2030
9.2.4. Central nervous system (CNS) disorders
9.2.4.1.
Definition
9.2.4.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.4.3.
Market
Forecast, 2022 - 2030
9.2.4.4.
Compound
Annual Growth Rate (CAGR)
9.2.4.5.
Regional
Bifurcation
9.2.4.5.1.
North
America
9.2.4.5.1.1. Market Estimation, 2015 - 2021
9.2.4.5.1.2. Market Forecast, 2022 - 2030
9.2.4.5.2.
Europe
9.2.4.5.2.1. Market Estimation, 2015 - 2021
9.2.4.5.2.2. Market Forecast, 2022 - 2030
9.2.4.5.3.
Asia
Pacific
9.2.4.5.3.1. Market Estimation, 2015 - 2021
9.2.4.5.3.2. Market Forecast, 2022 - 2030
9.2.4.5.4.
Middle
East and Africa
9.2.4.5.4.1. Market Estimation, 2015 - 2021
9.2.4.5.4.2. Market Forecast, 2022 - 2030
9.2.4.5.5.
Latin
America
9.2.4.5.5.1. Market Estimation, 2015 - 2021
9.2.4.5.5.2. Market Forecast, 2022 - 2030
9.2.5. Respiratory
9.2.5.1.
Definition
9.2.5.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.5.3.
Market
Forecast, 2022 - 2030
9.2.5.4.
Compound
Annual Growth Rate (CAGR)
9.2.5.5.
Regional
Bifurcation
9.2.5.5.1.
North
America
9.2.5.5.1.1. Market Estimation, 2015 - 2021
9.2.5.5.1.2. Market Forecast, 2022 - 2030
9.2.5.5.2.
Europe
9.2.5.5.2.1. Market Estimation, 2015 - 2021
9.2.5.5.2.2. Market Forecast, 2022 - 2030
9.2.5.5.3.
Asia
Pacific
9.2.5.5.3.1. Market Estimation, 2015 - 2021
9.2.5.5.3.2. Market Forecast, 2022 - 2030
9.2.5.5.4.
Middle
East and Africa
9.2.5.5.4.1. Market Estimation, 2015 - 2021
9.2.5.5.4.2. Market Forecast, 2022 - 2030
9.2.5.5.5.
Latin
America
9.2.5.5.5.1. Market Estimation, 2015 - 2021
9.2.5.5.5.2. Market Forecast, 2022 - 2030
9.2.6. Gastrointestinal
9.2.6.1.
Definition
9.2.6.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.6.3.
Market
Forecast, 2022 - 2030
9.2.6.4.
Compound
Annual Growth Rate (CAGR)
9.2.6.5.
Regional
Bifurcation
9.2.6.5.1.
North
America
9.2.6.5.1.1. Market Estimation, 2015 - 2021
9.2.6.5.1.2. Market Forecast, 2022 - 2030
9.2.6.5.2.
Europe
9.2.6.5.2.1. Market Estimation, 2015 - 2021
9.2.6.5.2.2. Market Forecast, 2022 - 2030
9.2.6.5.3.
Asia
Pacific
9.2.6.5.3.1. Market Estimation, 2015 - 2021
9.2.6.5.3.2. Market Forecast, 2022 - 2030
9.2.6.5.4.
Middle
East and Africa
9.2.6.5.4.1. Market Estimation, 2015 - 2021
9.2.6.5.4.2. Market Forecast, 2022 - 2030
9.2.6.5.5.
Latin
America
9.2.6.5.5.1. Market Estimation, 2015 - 2021
9.2.6.5.5.2. Market Forecast, 2022 - 2030
9.2.7. Others
9.2.7.1.
Definition
9.2.7.2.
Market
Estimation and Penetration, 2015 - 2021
9.2.7.3.
Market
Forecast, 2022 - 2030
9.2.7.4.
Compound
Annual Growth Rate (CAGR)
9.2.7.5.
Regional
Bifurcation
9.2.7.5.1.
North
America
9.2.7.5.1.1. Market Estimation, 2015 - 2021
9.2.7.5.1.2. Market Forecast, 2022 - 2030
9.2.7.5.2.
Europe
9.2.7.5.2.1. Market Estimation, 2015 - 2021
9.2.7.5.2.2. Market Forecast, 2022 - 2030
9.2.7.5.3.
Asia
Pacific
9.2.7.5.3.1. Market Estimation, 2015 - 2021
9.2.7.5.3.2. Market Forecast, 2022 - 2030
9.2.7.5.4.
Middle
East and Africa
9.2.7.5.4.1. Market Estimation, 2015 - 2021
9.2.7.5.4.2. Market Forecast, 2022 - 2030
9.2.7.5.5.
Latin
America
9.2.7.5.5.1. Market Estimation, 2015 - 2021
9.2.7.5.5.2. Market Forecast, 2022 - 2030
9.3. Key Segment for Channeling Investments
9.3.1. By Therapeutic Indication
10. Global Small Molecule Drug Discovery Market
Analysis and Forecasts, 2022 – 2030
10.1. Overview
10.2. Global Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
10.2.1. Pharmaceutical Companies
10.2.1.1. Definition
10.2.1.2. Market Estimation and Penetration, 2015 -
2021
10.2.1.3. Market Forecast, 2022 - 2030
10.2.1.4. Compound Annual Growth Rate (CAGR)
10.2.1.5. Regional Bifurcation
10.2.1.5.1. North America
10.2.1.5.1.1. Market Estimation, 2015 - 2021
10.2.1.5.1.2. Market Forecast, 2022 - 2030
10.2.1.5.2. Europe
10.2.1.5.2.1. Market Estimation, 2015 - 2021
10.2.1.5.2.2. Market Forecast, 2022 - 2030
10.2.1.5.3. Asia Pacific
10.2.1.5.3.1. Market Estimation, 2015 - 2021
10.2.1.5.3.2. Market Forecast, 2022 - 2030
10.2.1.5.4. Middle East and Africa
10.2.1.5.4.1. Market Estimation, 2015 - 2021
10.2.1.5.4.2. Market Forecast, 2022 - 2030
10.2.1.5.5. Latin America
10.2.1.5.5.1. Market Estimation, 2015 - 2021
10.2.1.5.5.2. Market Forecast, 2022 - 2030
10.2.2. Research Labs and Centers
10.2.2.1. Definition
10.2.2.2. Market Estimation and Penetration, 2015 -
2021
10.2.2.3. Market Forecast, 2022 - 2030
10.2.2.4. Compound Annual Growth Rate (CAGR)
10.2.2.5. Regional Bifurcation
10.2.2.5.1. North America
10.2.2.5.1.1. Market Estimation, 2015 - 2021
10.2.2.5.1.2. Market Forecast, 2022 - 2030
10.2.2.5.2. Europe
10.2.2.5.2.1. Market Estimation, 2015 - 2021
10.2.2.5.2.2. Market Forecast, 2022 - 2030
10.2.2.5.3. Asia Pacific
10.2.2.5.3.1. Market Estimation, 2015 - 2021
10.2.2.5.3.2. Market Forecast, 2022 - 2030
10.2.2.5.4. Middle East and Africa
10.2.2.5.4.1. Market Estimation, 2015 - 2021
10.2.2.5.4.2. Market Forecast, 2022 - 2030
10.2.2.5.5. Latin America
10.2.2.5.5.1. Market Estimation, 2015 - 2021
10.2.2.5.5.2. Market Forecast, 2022 - 2030
10.2.3. Others
10.2.3.1. Definition
10.2.3.2. Market Estimation and Penetration, 2015 -
2021
10.2.3.3. Market Forecast, 2022 - 2030
10.2.3.4. Compound Annual Growth Rate (CAGR)
10.2.3.5. Regional Bifurcation
10.2.3.5.1. North America
10.2.3.5.1.1. Market Estimation, 2015 - 2021
10.2.3.5.1.2. Market Forecast, 2022 - 2030
10.2.3.5.2. Europe
10.2.3.5.2.1. Market Estimation, 2015 - 2021
10.2.3.5.2.2. Market Forecast, 2022 - 2030
10.2.3.5.3. Asia Pacific
10.2.3.5.3.1. Market Estimation, 2015 - 2021
10.2.3.5.3.2. Market Forecast, 2022 - 2030
10.2.3.5.4. Middle East and Africa
10.2.3.5.4.1. Market Estimation, 2015 - 2021
10.2.3.5.4.2. Market Forecast, 2022 - 2030
10.2.3.5.5. Latin America
10.2.3.5.5.1. Market Estimation, 2015 - 2021
10.2.3.5.5.2. Market Forecast, 2022 - 2030
10.3. Key Segment for Channeling Investments
10.3.1. By End Users
11. North America Small Molecule Drug Discovery
Market Analysis and Forecasts, 2022 - 2030
11.1. Overview
11.1.1. North America Small Molecule Drug Discovery
Market Revenue (US$ Mn)
11.2. North America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
11.2.1. Target Validation and Identification
11.2.2. Hit and lead generation
11.2.3. Lead optimization and Profiling
11.2.4. Clinical Trials
11.3. North America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.3.1. Mental Disorder
11.3.2. Oncology
11.3.3. Cardiovascular
11.3.4. Central nervous system (CNS) disorders
11.3.5. Respiratory
11.3.6. Gastrointestinal
11.3.7. Others
11.4. North America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
11.4.1. Pharmaceutical Companies
11.4.2. Research Labs and Centers
11.4.3. Others
11.5. North America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Country
11.5.1. U.S
11.5.1.1. U.S Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
11.5.1.1.1. Target Validation and Identification
11.5.1.1.2. Hit and lead generation
11.5.1.1.3. Lead optimization and Profiling
11.5.1.1.4. Clinical Trials
11.5.1.2. U.S Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.1.2.1. Mental Disorder
11.5.1.2.2. Oncology
11.5.1.2.3. Cardiovascular
11.5.1.2.4. Central nervous system (CNS) disorders
11.5.1.2.5. Respiratory
11.5.1.2.6. Gastrointestinal
11.5.1.2.7. Others
11.5.1.3. U.S Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.1.3.1. Pharmaceutical Companies
11.5.1.3.2. Research Labs and Centers
11.5.1.3.3. Others
11.5.2. Canada
11.5.2.1. Canada Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
11.5.2.1.1. Target Validation and Identification
11.5.2.1.2. Hit and lead generation
11.5.2.1.3. Lead optimization and Profiling
11.5.2.1.4. Clinical Trials
11.5.2.2. Canada Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.2.2.1. Mental Disorder
11.5.2.2.2. Oncology
11.5.2.2.3. Cardiovascular
11.5.2.2.4. Central nervous system (CNS) disorders
11.5.2.2.5. Respiratory
11.5.2.2.6. Gastrointestinal
11.5.2.2.7. Others
11.5.2.3. Canada Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.2.3.1. Pharmaceutical Companies
11.5.2.3.2. Research Labs and Centers
11.5.2.3.3. Others
11.5.3. Mexico
11.5.3.1. Mexico Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
11.5.3.1.1. Target Validation and Identification
11.5.3.1.2. Hit and lead generation
11.5.3.1.3. Lead optimization and Profiling
11.5.3.1.4. Clinical Trials
11.5.3.2. Mexico Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.3.2.1. Mental Disorder
11.5.3.2.2. Oncology
11.5.3.2.3. Cardiovascular
11.5.3.2.4. Central nervous system (CNS) disorders
11.5.3.2.5. Respiratory
11.5.3.2.6. Gastrointestinal
11.5.3.2.7. Others
11.5.3.3. Mexico Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
11.5.3.3.1. Pharmaceutical Companies
11.5.3.3.2. Research Labs and Centers
11.5.3.3.3. Others
11.5.4. Rest of North America
11.5.4.1. Rest of North America Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Phase
11.5.4.1.1. Target Validation and Identification
11.5.4.1.2. Hit and lead generation
11.5.4.1.3. Lead optimization and Profiling
11.5.4.1.4. Clinical Trials
11.5.4.2. Rest of North America Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
11.5.4.2.1. Mental Disorder
11.5.4.2.2. Oncology
11.5.4.2.3. Cardiovascular
11.5.4.2.4. Central nervous system (CNS) disorders
11.5.4.2.5. Respiratory
11.5.4.2.6. Gastrointestinal
11.5.4.2.7. Others
11.5.4.3. Rest of North America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
11.5.4.3.1. Pharmaceutical Companies
11.5.4.3.2. Research Labs and Centers
11.5.4.3.3. Others
11.6. Key Segment for Channeling Investments
11.6.1. By Country
11.6.2. By Phase
11.6.3. By Therapeutic Indication
11.6.4. By End Users
12. Europe Small Molecule Drug Discovery Market
Analysis and Forecasts, 2022 - 2030
12.1. Overview
12.1.1. Europe Small Molecule Drug Discovery Market
Revenue (US$ Mn)
12.2. Europe Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
12.2.1. Target Validation and Identification
12.2.2. Hit and lead generation
12.2.3. Lead optimization and Profiling
12.2.4. Clinical Trials
12.3. Europe Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.3.1. Mental Disorder
12.3.2. Oncology
12.3.3. Cardiovascular
12.3.4. Central nervous system (CNS) disorders
12.3.5. Respiratory
12.3.6. Gastrointestinal
12.3.7. Others
12.4. Europe Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
12.4.1. Pharmaceutical Companies
12.4.2. Research Labs and Centers
12.4.3. Others
12.5. Europe Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Country
12.5.1. France
12.5.1.1. France Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
12.5.1.1.1. Target Validation and Identification
12.5.1.1.2. Hit and lead generation
12.5.1.1.3. Lead optimization and Profiling
12.5.1.1.4. Clinical Trials
12.5.1.2. France Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.1.2.1. Mental Disorder
12.5.1.2.2. Oncology
12.5.1.2.3. Cardiovascular
12.5.1.2.4. Central nervous system (CNS) disorders
12.5.1.2.5. Respiratory
12.5.1.2.6. Gastrointestinal
12.5.1.2.7. Others
12.5.1.3. France Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.1.3.1. Pharmaceutical Companies
12.5.1.3.2. Research Labs and Centers
12.5.1.3.3. Others
12.5.2. The UK
12.5.2.1. The UK Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
12.5.2.1.1. Target Validation and Identification
12.5.2.1.2. Hit and lead generation
12.5.2.1.3. Lead optimization and Profiling
12.5.2.1.4. Clinical Trials
12.5.2.2. The UK Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.2.2.1. Mental Disorder
12.5.2.2.2. Oncology
12.5.2.2.3. Cardiovascular
12.5.2.2.4. Central nervous system (CNS) disorders
12.5.2.2.5. Respiratory
12.5.2.2.6. Gastrointestinal
12.5.2.2.7. Others
12.5.2.3. The UK Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.2.3.1. Pharmaceutical Companies
12.5.2.3.2. Research Labs and Centers
12.5.2.3.3. Others
12.5.3. Spain
12.5.3.1. Spain Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
12.5.3.1.1. Target Validation and Identification
12.5.3.1.2. Hit and lead generation
12.5.3.1.3. Lead optimization and Profiling
12.5.3.1.4. Clinical Trials
12.5.3.2. Spain Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.3.2.1. Mental Disorder
12.5.3.2.2. Oncology
12.5.3.2.3. Cardiovascular
12.5.3.2.4. Central nervous system (CNS) disorders
12.5.3.2.5. Respiratory
12.5.3.2.6. Gastrointestinal
12.5.3.2.7. Others
12.5.3.3. Spain Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.3.3.1. Pharmaceutical Companies
12.5.3.3.2. Research Labs and Centers
12.5.3.3.3. Others
12.5.4. Germany
12.5.4.1. Germany Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
12.5.4.1.1. Target Validation and Identification
12.5.4.1.2. Hit and lead generation
12.5.4.1.3. Lead optimization and Profiling
12.5.4.1.4. Clinical Trials
12.5.4.2. Germany Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.4.2.1. Mental Disorder
12.5.4.2.2. Oncology
12.5.4.2.3. Cardiovascular
12.5.4.2.4. Central nervous system (CNS) disorders
12.5.4.2.5. Respiratory
12.5.4.2.6. Gastrointestinal
12.5.4.2.7. Others
12.5.4.3. Germany Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.4.3.1. Pharmaceutical Companies
12.5.4.3.2. Research Labs and Centers
12.5.4.3.3. Others
12.5.5. Italy
12.5.5.1. Italy Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
12.5.5.1.1. Target Validation and Identification
12.5.5.1.2. Hit and lead generation
12.5.5.1.3. Lead optimization and Profiling
12.5.5.1.4. Clinical Trials
12.5.5.2. Italy Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.5.2.1. Mental Disorder
12.5.5.2.2. Oncology
12.5.5.2.3. Cardiovascular
12.5.5.2.4. Central nervous system (CNS) disorders
12.5.5.2.5. Respiratory
12.5.5.2.6. Gastrointestinal
12.5.5.2.7. Others
12.5.5.3. Italy Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
12.5.5.3.1. Pharmaceutical Companies
12.5.5.3.2. Research Labs and Centers
12.5.5.3.3. Others
12.5.6. Nordic Countries
12.5.6.1. Nordic Countries Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Phase
12.5.6.1.1. Target Validation and Identification
12.5.6.1.2. Hit and lead generation
12.5.6.1.3. Lead optimization and Profiling
12.5.6.1.4. Clinical Trials
12.5.6.2. Nordic Countries Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.6.2.1. Mental Disorder
12.5.6.2.2. Oncology
12.5.6.2.3. Cardiovascular
12.5.6.2.4. Central nervous system (CNS) disorders
12.5.6.2.5. Respiratory
12.5.6.2.6. Gastrointestinal
12.5.6.2.7. Others
12.5.6.3. Nordic Countries Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.6.3.1. Pharmaceutical Companies
12.5.6.3.2. Research Labs and Centers
12.5.6.3.3. Others
12.5.6.4. Nordic Countries Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Country
12.5.6.4.1. Denmark
12.5.6.4.2. Finland
12.5.6.4.3. Iceland
12.5.6.4.4. Sweden
12.5.6.4.5. Norway
12.5.7. Benelux Union
12.5.7.1. Benelux Union Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
12.5.7.1.1. Target Validation and Identification
12.5.7.1.2. Hit and lead generation
12.5.7.1.3. Lead optimization and Profiling
12.5.7.1.4. Clinical Trials
12.5.7.2. Benelux Union Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.7.2.1. Mental Disorder
12.5.7.2.2. Oncology
12.5.7.2.3. Cardiovascular
12.5.7.2.4. Central nervous system (CNS) disorders
12.5.7.2.5. Respiratory
12.5.7.2.6. Gastrointestinal
12.5.7.2.7. Others
12.5.7.3. Benelux Union Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.7.3.1. Pharmaceutical Companies
12.5.7.3.2. Research Labs and Centers
12.5.7.3.3. Others
12.5.7.4. Benelux Union Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Country
12.5.7.4.1. Belgium
12.5.7.4.2. The Netherlands
12.5.7.4.3. Luxembourg
12.5.8. Rest of Europe
12.5.8.1. Rest of Europe Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
12.5.8.1.1. Target Validation and Identification
12.5.8.1.2. Hit and lead generation
12.5.8.1.3. Lead optimization and Profiling
12.5.8.1.4. Clinical Trials
12.5.8.2. Rest of Europe Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
12.5.8.2.1. Mental Disorder
12.5.8.2.2. Oncology
12.5.8.2.3. Cardiovascular
12.5.8.2.4. Central nervous system (CNS) disorders
12.5.8.2.5. Respiratory
12.5.8.2.6. Gastrointestinal
12.5.8.2.7. Others
12.5.8.3. Rest of Europe Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
12.5.8.3.1. Pharmaceutical Companies
12.5.8.3.2. Research Labs and Centers
12.5.8.3.3. Others
12.6. Key Segment for Channeling Investments
12.6.1. By Country
12.6.2. By Phase
12.6.3. By Therapeutic Indication
12.6.4. By End Users
13. Asia Pacific Small Molecule Drug Discovery
Market Analysis and Forecasts, 2022 - 2030
13.1. Overview
13.1.1. Asia Pacific Small Molecule Drug Discovery
Market Revenue (US$ Mn)
13.2. Asia Pacific Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
13.2.1. Target Validation and Identification
13.2.2. Hit and lead generation
13.2.3. Lead optimization and Profiling
13.2.4. Clinical Trials
13.3. Asia Pacific Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.3.1. Mental Disorder
13.3.2. Oncology
13.3.3. Cardiovascular
13.3.4. Central nervous system (CNS) disorders
13.3.5. Respiratory
13.3.6. Gastrointestinal
13.3.7. Others
13.4. Asia Pacific Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
13.4.1. Pharmaceutical Companies
13.4.2. Research Labs and Centers
13.4.3. Others
13.5. Asia Pacific Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Country
13.5.1. China
13.5.1.1. China Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
13.5.1.1.1. Target Validation and Identification
13.5.1.1.2. Hit and lead generation
13.5.1.1.3. Lead optimization and Profiling
13.5.1.1.4. Clinical Trials
13.5.1.2. China Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.1.2.1. Mental Disorder
13.5.1.2.2. Oncology
13.5.1.2.3. Cardiovascular
13.5.1.2.4. Central nervous system (CNS) disorders
13.5.1.2.5. Respiratory
13.5.1.2.6. Gastrointestinal
13.5.1.2.7. Others
13.5.1.3. China Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
13.5.1.3.1. Pharmaceutical Companies
13.5.1.3.2. Research Labs and Centers
13.5.1.3.3. Others
13.5.2. Japan
13.5.2.1. Japan Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
13.5.2.1.1. Target Validation and Identification
13.5.2.1.2. Hit and lead generation
13.5.2.1.3. Lead optimization and Profiling
13.5.2.1.4. Clinical Trials
13.5.2.2. Japan Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.2.2.1. Mental Disorder
13.5.2.2.2. Oncology
13.5.2.2.3. Cardiovascular
13.5.2.2.4. Central nervous system (CNS) disorders
13.5.2.2.5. Respiratory
13.5.2.2.6. Gastrointestinal
13.5.2.2.7. Others
13.5.2.3. Japan Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
13.5.2.3.1. Pharmaceutical Companies
13.5.2.3.2. Research Labs and Centers
13.5.2.3.3. Others
13.5.3. India
13.5.3.1. India Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
13.5.3.1.1. Target Validation and Identification
13.5.3.1.2. Hit and lead generation
13.5.3.1.3. Lead optimization and Profiling
13.5.3.1.4. Clinical Trials
13.5.3.2. India Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.3.2.1. Mental Disorder
13.5.3.2.2. Oncology
13.5.3.2.3. Cardiovascular
13.5.3.2.4. Central nervous system (CNS) disorders
13.5.3.2.5. Respiratory
13.5.3.2.6. Gastrointestinal
13.5.3.2.7. Others
13.5.3.3. India Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
13.5.3.3.1. Pharmaceutical Companies
13.5.3.3.2. Research Labs and Centers
13.5.3.3.3. Others
13.5.4. New Zealand
13.5.4.1. New Zealand Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
13.5.4.1.1. Target Validation and Identification
13.5.4.1.2. Hit and lead generation
13.5.4.1.3. Lead optimization and Profiling
13.5.4.1.4. Clinical Trials
13.5.4.2. New Zealand Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.4.2.1. Mental Disorder
13.5.4.2.2. Oncology
13.5.4.2.3. Cardiovascular
13.5.4.2.4. Central nervous system (CNS) disorders
13.5.4.2.5. Respiratory
13.5.4.2.6. Gastrointestinal
13.5.4.2.7. Others
13.5.4.3. New Zealand Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.4.3.1. Pharmaceutical Companies
13.5.4.3.2. Research Labs and Centers
13.5.4.3.3. Others
13.5.5. Australia
13.5.5.1. Australia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
13.5.5.1.1. Target Validation and Identification
13.5.5.1.2. Hit and lead generation
13.5.5.1.3. Lead optimization and Profiling
13.5.5.1.4. Clinical Trials
13.5.5.2. Australia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.5.2.1. Mental Disorder
13.5.5.2.2. Oncology
13.5.5.2.3. Cardiovascular
13.5.5.2.4. Central nervous system (CNS) disorders
13.5.5.2.5. Respiratory
13.5.5.2.6. Gastrointestinal
13.5.5.2.7. Others
13.5.5.3. Australia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.5.3.1. Pharmaceutical Companies
13.5.5.3.2. Research Labs and Centers
13.5.5.3.3. Others
13.5.6. South Korea
13.5.6.1. South Korea Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
13.5.6.1.1. Target Validation and Identification
13.5.6.1.2. Hit and lead generation
13.5.6.1.3. Lead optimization and Profiling
13.5.6.1.4. Clinical Trials
13.5.6.2. South Korea Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.6.2.1. Mental Disorder
13.5.6.2.2. Oncology
13.5.6.2.3. Cardiovascular
13.5.6.2.4. Central nervous system (CNS) disorders
13.5.6.2.5. Respiratory
13.5.6.2.6. Gastrointestinal
13.5.6.2.7. Others
13.5.6.3. South Korea Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.6.3.1. Pharmaceutical Companies
13.5.6.3.2. Research Labs and Centers
13.5.6.3.3. Others
13.5.7. Southeast Asia
13.5.7.1. Southeast Asia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
13.5.7.1.1. Target Validation and Identification
13.5.7.1.2. Hit and lead generation
13.5.7.1.3. Lead optimization and Profiling
13.5.7.1.4. Clinical Trials
13.5.7.2. Southeast Asia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.7.2.1. Mental Disorder
13.5.7.2.2. Oncology
13.5.7.2.3. Cardiovascular
13.5.7.2.4. Central nervous system (CNS) disorders
13.5.7.2.5. Respiratory
13.5.7.2.6. Gastrointestinal
13.5.7.2.7. Others
13.5.7.3. Southeast Asia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.7.3.1. Pharmaceutical Companies
13.5.7.3.2. Research Labs and Centers
13.5.7.3.3. Others
13.5.7.4. Southeast Asia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Country
13.5.7.4.1. Indonesia
13.5.7.4.2. Thailand
13.5.7.4.3. Malaysia
13.5.7.4.4. Singapore
13.5.7.4.5. Rest of Southeast Asia
13.5.8. Rest of Asia Pacific
13.5.8.1. Rest of Asia Pacific Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Phase
13.5.8.1.1. Target Validation and Identification
13.5.8.1.2. Hit and lead generation
13.5.8.1.3. Lead optimization and Profiling
13.5.8.1.4. Clinical Trials
13.5.8.2. Rest of Asia Pacific Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
13.5.8.2.1. Mental Disorder
13.5.8.2.2. Oncology
13.5.8.2.3. Cardiovascular
13.5.8.2.4. Central nervous system (CNS) disorders
13.5.8.2.5. Respiratory
13.5.8.2.6. Gastrointestinal
13.5.8.2.7. Others
13.5.8.3. Rest of Asia Pacific Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By End Users
13.5.8.3.1. Pharmaceutical Companies
13.5.8.3.2. Research Labs and Centers
13.5.8.3.3. Others
13.6. Key Segment for Channeling Investments
13.6.1. By Country
13.6.2. By Phase
13.6.3. By Therapeutic Indication
13.6.4. By End Users
14. Middle East and Africa Small Molecule Drug
Discovery Market Analysis and Forecasts, 2022 - 2030
14.1. Overview
14.1.1. Middle East and Africa Small Molecule Drug
Discovery Market Revenue (US$ Mn)
14.2. Middle East and Africa Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Phase
14.2.1. Target Validation and Identification
14.2.2. Hit and lead generation
14.2.3. Lead optimization and Profiling
14.2.4. Clinical Trials
14.3. Middle East and Africa Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.3.1. Mental Disorder
14.3.2. Oncology
14.3.3. Cardiovascular
14.3.4. Central nervous system (CNS) disorders
14.3.5. Respiratory
14.3.6. Gastrointestinal
14.3.7. Others
14.4. Middle East and Africa Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By End Users
14.4.1. Pharmaceutical Companies
14.4.2. Research Labs and Centers
14.4.3. Others
14.5. Middle East and Africa Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Country
14.5.1. Saudi Arabia
14.5.1.1. Saudi Arabia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
14.5.1.1.1. Target Validation and Identification
14.5.1.1.2. Hit and lead generation
14.5.1.1.3. Lead optimization and Profiling
14.5.1.1.4. Clinical Trials
14.5.1.2. Saudi Arabia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.1.2.1. Mental Disorder
14.5.1.2.2. Oncology
14.5.1.2.3. Cardiovascular
14.5.1.2.4. Central nervous system (CNS) disorders
14.5.1.2.5. Respiratory
14.5.1.2.6. Gastrointestinal
14.5.1.2.7. Others
14.5.1.3. Saudi Arabia Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.1.3.1. Pharmaceutical Companies
14.5.1.3.2. Research Labs and Centers
14.5.1.3.3. Others
14.5.2. UAE
14.5.2.1. UAE Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
14.5.2.1.1. Target Validation and Identification
14.5.2.1.2. Hit and lead generation
14.5.2.1.3. Lead optimization and Profiling
14.5.2.1.4. Clinical Trials
14.5.2.2. UAE Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.2.2.1. Mental Disorder
14.5.2.2.2. Oncology
14.5.2.2.3. Cardiovascular
14.5.2.2.4. Central nervous system (CNS) disorders
14.5.2.2.5. Respiratory
14.5.2.2.6. Gastrointestinal
14.5.2.2.7. Others
14.5.2.3. UAE Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.2.3.1. Pharmaceutical Companies
14.5.2.3.2. Research Labs and Centers
14.5.2.3.3. Others
14.5.3. Egypt
14.5.3.1. Egypt Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
14.5.3.1.1. Target Validation and Identification
14.5.3.1.2. Hit and lead generation
14.5.3.1.3. Lead optimization and Profiling
14.5.3.1.4. Clinical Trials
14.5.3.2. Egypt Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.3.2.1. Mental Disorder
14.5.3.2.2. Oncology
14.5.3.2.3. Cardiovascular
14.5.3.2.4. Central nervous system (CNS) disorders
14.5.3.2.5. Respiratory
14.5.3.2.6. Gastrointestinal
14.5.3.2.7. Others
14.5.3.3. Egypt Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.3.3.1. Pharmaceutical Companies
14.5.3.3.2. Research Labs and Centers
14.5.3.3.3. Others
14.5.4. Kuwait
14.5.4.1. Kuwait Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
14.5.4.1.1. Target Validation and Identification
14.5.4.1.2. Hit and lead generation
14.5.4.1.3. Lead optimization and Profiling
14.5.4.1.4. Clinical Trials
14.5.4.2. Kuwait Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.4.2.1. Mental Disorder
14.5.4.2.2. Oncology
14.5.4.2.3. Cardiovascular
14.5.4.2.4. Central nervous system (CNS) disorders
14.5.4.2.5. Respiratory
14.5.4.2.6. Gastrointestinal
14.5.4.2.7. Others
14.5.4.3. Kuwait Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
14.5.4.3.1. Pharmaceutical Companies
14.5.4.3.2. Research Labs and Centers
14.5.4.3.3. Others
14.5.5. South Africa
14.5.5.1. South Africa Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
14.5.5.1.1. Target Validation and Identification
14.5.5.1.2. Hit and lead generation
14.5.5.1.3. Lead optimization and Profiling
14.5.5.1.4. Clinical Trials
14.5.5.2. South Africa Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
14.5.5.2.1. Mental Disorder
14.5.5.2.2. Oncology
14.5.5.2.3. Cardiovascular
14.5.5.2.4. Central nervous system (CNS) disorders
14.5.5.2.5. Respiratory
14.5.5.2.6. Gastrointestinal
14.5.5.2.7. Others
14.5.5.3. South Africa Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.5.3.1. Pharmaceutical Companies
14.5.5.3.2. Research Labs and Centers
14.5.5.3.3. Others
14.5.6. Rest of Middle East & Africa
14.5.6.1. Rest of Middle East & Africa Small
Molecule Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Phase
14.5.6.1.1. Target Validation and Identification
14.5.6.1.2. Hit and lead generation
14.5.6.1.3. Lead optimization and Profiling
14.5.6.1.4. Clinical Trials
14.5.6.2. Rest of Middle East & Africa Small
Molecule Drug Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic
Indication
14.5.6.2.1. Mental Disorder
14.5.6.2.2. Oncology
14.5.6.2.3. Cardiovascular
14.5.6.2.4. Central nervous system (CNS) disorders
14.5.6.2.5. Respiratory
14.5.6.2.6. Gastrointestinal
14.5.6.2.7. Others
14.5.6.3. Rest of Middle East & Africa Small
Molecule Drug Discovery Market Revenue (US$ Mn) and Forecasts, By End Users
14.5.6.3.1. Pharmaceutical Companies
14.5.6.3.2. Research Labs and Centers
14.5.6.3.3. Others
14.6. Key Segment for Channeling Investments
14.6.1. By Country
14.6.2. By Phase
14.6.3. By Therapeutic Indication
14.6.4. By End Users
15. Latin America Small Molecule Drug Discovery
Market Analysis and Forecasts, 2022 - 2030
15.1. Overview
15.1.1. Latin America Small Molecule Drug Discovery
Market Revenue (US$ Mn)
15.2. Latin America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
15.2.1. Target Validation and Identification
15.2.2. Hit and lead generation
15.2.3. Lead optimization and Profiling
15.2.4. Clinical Trials
15.3. Latin America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.3.1. Mental Disorder
15.3.2. Oncology
15.3.3. Cardiovascular
15.3.4. Central nervous system (CNS) disorders
15.3.5. Respiratory
15.3.6. Gastrointestinal
15.3.7. Others
15.4. Latin America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
15.4.1. Pharmaceutical Companies
15.4.2. Research Labs and Centers
15.4.3. Others
15.5. Latin America Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Country
15.5.1. Brazil
15.5.1.1. Brazil Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Phase
15.5.1.1.1. Target Validation and Identification
15.5.1.1.2. Hit and lead generation
15.5.1.1.3. Lead optimization and Profiling
15.5.1.1.4. Clinical Trials
15.5.1.2. Brazil Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.5.1.2.1. Mental Disorder
15.5.1.2.2. Oncology
15.5.1.2.3. Cardiovascular
15.5.1.2.4. Central nervous system (CNS) disorders
15.5.1.2.5. Respiratory
15.5.1.2.6. Gastrointestinal
15.5.1.2.7. Others
15.5.1.3. Brazil Small Molecule Drug Discovery Market
Revenue (US$ Mn) and Forecasts, By End Users
15.5.1.3.1. Pharmaceutical Companies
15.5.1.3.2. Research Labs and Centers
15.5.1.3.3. Others
15.5.2. Argentina
15.5.2.1. Argentina Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Phase
15.5.2.1.1. Target Validation and Identification
15.5.2.1.2. Hit and lead generation
15.5.2.1.3. Lead optimization and Profiling
15.5.2.1.4. Clinical Trials
15.5.2.2. Argentina Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.5.2.2.1. Mental Disorder
15.5.2.2.2. Oncology
15.5.2.2.3. Cardiovascular
15.5.2.2.4. Central nervous system (CNS) disorders
15.5.2.2.5. Respiratory
15.5.2.2.6. Gastrointestinal
15.5.2.2.7. Others
15.5.2.3. Argentina Small Molecule Drug Discovery
Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.2.3.1. Pharmaceutical Companies
15.5.2.3.2. Research Labs and Centers
15.5.2.3.3. Others
15.5.3. Rest of Latin America
15.5.3.1. Rest of Latin America Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Phase
15.5.3.1.1. Target Validation and Identification
15.5.3.1.2. Hit and lead generation
15.5.3.1.3. Lead optimization and Profiling
15.5.3.1.4. Clinical Trials
15.5.3.2. Rest of Latin America Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By Therapeutic Indication
15.5.3.2.1. Mental Disorder
15.5.3.2.2. Oncology
15.5.3.2.3. Cardiovascular
15.5.3.2.4. Central nervous system (CNS) disorders
15.5.3.2.5. Respiratory
15.5.3.2.6. Gastrointestinal
15.5.3.2.7. Others
15.5.3.3. Rest of Latin America Small Molecule Drug
Discovery Market Revenue (US$ Mn) and Forecasts, By End Users
15.5.3.3.1. Pharmaceutical Companies
15.5.3.3.2. Research Labs and Centers
15.5.3.3.3. Others
15.6. Key Segment for Channeling Investments
15.6.1. By Country
15.6.2. By Phase
15.6.3. By Therapeutic Indication
15.6.4. By End Users
16. Competitive Benchmarking
16.1. Brand Benchmarking
16.2. Market Share Analysis, 2021
16.3. Global Presence and Growth Strategies
16.3.1. Mergers and Acquisitions
16.3.2. Product Launches
16.3.3. Investments Trends
16.3.4. R&D Initiatives
17. Player Profiles
17.1. AbbVie Inc.
17.1.1. Company Details
17.1.2. Company Overview
17.1.3. Product Offerings
17.1.4. Key Developments
17.1.5. Financial Analysis
17.1.6. SWOT Analysis
17.1.7. Business Strategies
17.2. Boehringer Ingelheim International GmbH
17.2.1. Company Details
17.2.2. Company Overview
17.2.3. Product Offerings
17.2.4. Key Developments
17.2.5. Financial Analysis
17.2.6. SWOT Analysis
17.2.7. Business Strategies
17.3. Bristol-Myers Squibb Company
17.3.1. Company Details
17.3.2. Company Overview
17.3.3. Product Offerings
17.3.4. Key Developments
17.3.5. Financial Analysis
17.3.6. SWOT Analysis
17.3.7. Business Strategies
17.4. Charles River Laboratories
17.4.1. Company Details
17.4.2. Company Overview
17.4.3. Product Offerings
17.4.4. Key Developments
17.4.5. Financial Analysis
17.4.6. SWOT Analysis
17.4.7. Business Strategies
17.5. Eli Lilly and Company
17.5.1. Company Details
17.5.2. Company Overview
17.5.3. Product Offerings
17.5.4. Key Developments
17.5.5. Financial Analysis
17.5.6. SWOT Analysis
17.5.7. Business Strategies
17.6. Gilead Sciences, Inc.
17.6.1. Company Details
17.6.2. Company Overview
17.6.3. Product Offerings
17.6.4. Key Developments
17.6.5. Financial Analysis
17.6.6. SWOT Analysis
17.6.7. Business Strategies
17.7. GlaxoSmithKline plc
17.7.1. Company Details
17.7.2. Company Overview
17.7.3. Product Offerings
17.7.4. Key Developments
17.7.5. Financial Analysis
17.7.6. SWOT Analysis
17.7.7. Business Strategies
17.8. Johnson and Johnson Services, Inc.
17.8.1. Company Details
17.8.2. Company Overview
17.8.3. Product Offerings
17.8.4. Key Developments
17.8.5. Financial Analysis
17.8.6. SWOT Analysis
17.8.7. Business Strategies
17.9. Labcorp Drug Development
17.9.1. Company Details
17.9.2. Company Overview
17.9.3. Product Offerings
17.9.4. Key Developments
17.9.5. Financial Analysis
17.9.6. SWOT Analysis
17.9.7. Business Strategies
17.10. Merck KGaA
17.10.1. Company Details
17.10.2. Company Overview
17.10.3. Product Offerings
17.10.4. Key Developments
17.10.5. Financial Analysis
17.10.6. SWOT Analysis
17.10.7. Business Strategies
17.11. Pfizer Inc.
17.11.1. Company Details
17.11.2. Company Overview
17.11.3. Product Offerings
17.11.4. Key Developments
17.11.5. Financial Analysis
17.11.6. SWOT Analysis
17.11.7. Business Strategies
17.12. Teva Pharmaceutical Industries Ltd.
17.12.1. Company Details
17.12.2. Company Overview
17.12.3. Product Offerings
17.12.4. Key Developments
17.12.5. Financial Analysis
17.12.6. SWOT Analysis
17.12.7. Business Strategies
17.13. Other Market Participants
18. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User
and Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
